Abstract: A method of preventing or alleviating pain by administering to a human or other mammal in need thereof of a pain preventing or alleviating effective amount of a pharmaceutical composition comprising at least one specific isomer of inositol triphosphate.

Abstract: Novel acids, esters, and salts of phenyl, naphthyl, quinoxalinyl, and biphenyl bisphosphonic acids and 1,2-oxaphosphepins are described. These compounds are useful as antiinflammatory and anti-arthritic agents. Also described are known compounds of the phenyl, naphthyl, quinoxalinyl, and biphenyl bisphosphonate classes which are also useful as antiinflammatory and anti-arthritic agents. Representative compounds include [1,2-phenyldiyl]bis(methylene)bisphosphonic acid tetramethyl ester, [2,3-quinoxalindiyl]bis(methylene)bisphosphonic acid tetramethyl ester, [[3-(propyl)-4-(methoxy)-1,8-naphthalenediyl]bis(methylene)]bisphosphonic acid tetramethyl ester, [2,6-naphthalenediylbis(methylene)bisphosphonic acid tetraethyl ester, and [2,2'-biphenylenebis(methyl)]bisphosphonic acid tetramethyl ester. Representative oxaphosphepins include the preferred 3,4-dihydro-3-methoxy-7-(phenylmethoxy)-1H-naphth[1,8de][1,2]oxaphosphepin -3-oxide.

Abstract: The invention relates to a novel advantageous oral dosage form for methanediphosphonates, especially the active ingredient disodium pamidronate. A preferred dosage form comprises:a) disodium-3-amino-1-hydroxypropane-1,1-diphosphonate (disodium pamidronate),b) a cationic macroporous ion exchange resin based on a styrene/divinylbenzene copolymer having an exchangeable aminophosphonate group and, where appropriate,c) further pharmaceutically acceptable excipients.The ingredients can be processed to form tablets, dragees, capsules etc.

Abstract: A method of preventing or alleviating tissue damage, diabetes and complications thereof, bone disorders, disorders related to transplantation, disorders related to abnormal levels of lipoproteins, cardiovascular disease and inflammatory disorders by providing a mammal having one or more of the above diseases with a preventing or an alleviating effective amount of a compound having the formula C.sub.6 H.sub.6 (OH).sub.6-n (OPO.sub.3 H.sub.2).sub.n, where n is an integer of 1 or 2.

Abstract: A method of preventing or alleviating renal disorders by administering to a human or an animal in need thereof a pharmaceutical composition comprising an effective amount amount of at least one specific isomer of inositol trisphosphate sufficient to obtain said prevention or alleviation.

Abstract: The present invention relates to the use of inositoltrisphosphate (IP.sub.3) for the preparing of a medicament effective as a neuropeptide Y- (NPY-) antagonist and to a pharmaceutical composition comprising at least one specific isomer of IP.sub.3 and a pharmaceutically active compound effective in the cardiovascular, renal and/or cerebral area.

Abstract: A drug is described which includes a physico-chemical complex between molecules of a phospholipid and an aminoketone derivative of fluoroglucinol which is useful, particularly when administered topically in the form of a liposomal aqueous microdispersion, for increasing the microcirculatory flow-rate and volume in the capillaries to the skin, both in normal conditions and in peripheral vasculopathy (primary or secondary Raynaud's disease), acrocyanosis and blocked arteries caused by arteriosclerosis, diabetes or endoangioitis obliterans.

Abstract: This invention is directed to a non-invasive, topical treatment for telangiectasia, a dermatological condition commonly known as spider veins. The treatment preferably includes repeated applications of a composition having an effective amount of an inositol phosphoric acid or derivatives and mixtures thereof. Inositol hexaphosphate (phytic acid) is most preferred, with or without the use of a compression stocking.

Abstract: Compositions and methods for protecting the luminal lining against gastric acid challenge are disclosed. The compositions provide effective anti-ulcer preparations which include phosphorylated alcohol. Phosphorylated alcohols comprise the active anti-ulcerogenic ingredient of the described therapeutic formulations. The preparation of unique linear and cyclic polyphosphorylated alcohols and methods of using same to protect the stomach luminal lining against acid challenge are also disclosed. Inositol hexaphosphate and mannitol hexaphosphate are demonstrated to provide therapeutic value in the treatment and prevention of gastro-erosive disease precipitated by exposure of biological tissues to highly acidic substances, for example, the gastric digestive acids. While inositol hexaphosphate alone at subthreshold concentrations provides a small gastro-protective activity, a combination of inositol hexaphosphate (at subthreshold concentrations) with polyvalent cations, such as Au.sup.+3 or Bi.sup.

Abstract: A method of reducing the negative effect of cadmium or aluminum ion or free-radicals in body tissues and a method of alleviating cardiovascular diseases and conditions by administering to a human or an animal a pharmaceutical composition comprising an amount of at least one specific isomer of inositol triphosphate sufficient to obtain said alleviation.

Abstract: A method of preventing or alleviating certain conditions by administering to a human or an animal a pharmaceutical composition comprising an amount of at least one specific isomer of inositol trisphosphate sufficient to obtain said prevention or alleviation.

Abstract: A method for purifying two distinct insulin mediators to substantial homogeneity, and relative purity values above 80%, comprises adsorption on first anion exchange resin and subsequently on a chelex cation exchange resin column. The chelex resin ion exchange column substantially increases the activity of the recovered mediator. Following purification, the already treated fraction is subjected to three successive thin layer chromatography purification steps, the last giving, in the presence of ninhydrin stain, a characteristic salmon-color spot, which is indicative of the presence of the mediator. This process can also be used as a screening process, the absence of the salmon-colored spot being indicative of the diabetic state. Structure information on the insulin mediators obtained is given.

Abstract: An acaricidal composition comprising as active ingredients(A) either .alpha.-cyano-3-phenoxybenzyl 2,2,3,3-tetramethylcyclopropanecarboxylate or .alpha.-cyano-3-phenoxybenzyl N-(2-chloro-.alpha.,.alpha.,.alpha.-trifluor o-p-tolyl)-valinate, and(B) O,O,O',O'-tetraethyl S,S'-methylene bis(phosphorodithioate), is very effectively applicable as a composition for controlling acarine pests such as two-spotted spider mite (Tetranychus urticae Koch), carmine spider mite (Tetranychus cinnabarinus Boisduval), Kanazawa spider mite (Tetranychus Kansawai Kishida), citrus red mite (Panonychus citri McGregor), European red mite (Panonychus ulmi Koch), broad mite (Polyphagotarsonemus latus Banks), etc. in areas cultivated with fruit trees, tea-plant, vegetables, flowering plants, etc.

Abstract: A novel composition contains phytic acid and ferric ions as main ingredients and carboxylic acid ions as a dissolution accelerator, and may further include at least one or more or two additives selected from the group consisting of a carboxylic acid or its salt, saccharides, an amino acid or its salt and an organic phosphoric acid or its salt.

Abstract: A method of preventing or alleviating tissue or bone damage in mammals is disclosed. The method comprises administering, to a mammal, a tissue damage or a bone damage preventing or alleviating effective amount of a pharmaceutical composition which includes at least one isomer of inositol trisphosphate.

Abstract: A method of reducing the negative effects of heavy metals and a method of preventing or alleviating immunodeficiency, hypertension and dermatitis in mammals is disclosed. In these methods pharmaceutical compositions are administered to a mammal in need thereof. The particular pharmaceutical composition includes a reducing, preventing or alleviating effective amount, for the particular condition, of at least one isomer of inositol triphosphate.

Abstract: The invention relates to an emulsifiable microemulsion concentrate containing a phophoric acid ester and/or thiophosphoric acid ester as active ingredient. In addition to 20 to 80% by weight of active ingredient, the composition comprises: 7 to 70% by weight of a nonionic surface active agent, preferably a block copolymer with a molecular weight of 1000 to 10000 formed from polyethylene oxide and polypropylene oxide, an alkylphenol polyglycol ether, ethoxylated fatty alcohol or a mixture of nonionic surface active agents; 2 to 50% by weight of water; if desired, 1 to 50% by weight of a co-surfactant, preferably C.sub.1-8 straight or branched chain and/or cyclic alcohol, C.sub.3-8 straight or branched chain and/or cyclic ketone, esters of C.sub.1-6 fatty acids with C.sub.1-6 alcohols or the mixture thereof; and if desired, 15 to 30% by weight of a water-immiscible organic solvent.

Abstract: (Cycloalkylamino)methylenebis(phosphonic acid) represented by the general formula: ##STR1## in which, R, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 represent a hydrogen atom or a lower alkyl group, and n represents an integer from 3 to 10, a lower alkyl ester thereof or a pharmaceutically acceptable salt thereof; and a bone-resorption inhibitor and an anti-arthritis containing the same.

Abstract: Bacterial endotoxins are inhibited by a non-toxic, water-soluble, pharmaceutically acceptable peroxydiphosphate compound in contact with bacterial endotoxin.

Abstract: A method of treating diabetes or complications of diabetes is disclosed. In this method a pharmaceutically effective amount of at least one isomer of inositol triphosphate is administered to a human or an animal in need thereof.

Abstract: A method of reducing the negative effect of cadmium or aluminum ion or free-radicals in body tissues and a method of preventing or alleviating certain diseases and conditions by administering to a human or an animal a pharmaceutical composition comprising an amount of at least one specific isomer of inositol triphosphate sufficient to obtain said prevention or alleviation.

Abstract: A method of preventing or alleviating tissue or bone damage in mammals is disclosed. The method comprises administering, to a mammal, a tissue damage or a bone damage preventing or alleviating effective amount of a pharmaceutical composition which includes at least one isomer of inositol trisphosphate.

Abstract: A method of reducing or eliminating adverse effects of a pharmaceutical composition or a drug is disclosed. The method comprises administering to an animal or a human an amount of at least one specific isomer of inositol triphosphate sufficient to reduce or eliminate said adverse effects.

Abstract: Potent, specific inhibitors of phospholipase A.sub.2 are disclosed which are compounds of the formula: ##STR1## wherein A is R.sub.1 CO.sub.2 or OH, B is R.sub.2 CO.sub.2 or OH, D is R.sub.3 CO.sub.2 or OH and C is R.sub.4 CO.sub.2 ; and wherein R.sub.1, R.sub.2, and R.sub.3 and R.sub.4 are each C.sub.10 -C.sub.30 alkyl groups comprising from about 0-3 double bonds.

Abstract: A method is provided for inhibiting tumor growth by administering to a subject an effective tumor-inhibiting amount of a compound selected from the group consisting of phytic acid, phytate salt, an isomer or hydrolysate of phytic acid or phytate salt, or a mixture of any combination thereof. The preferred method of administration is by oral dosages of about 2 to 4 grams/kilogram bodyweight per day.

Abstract: Remedies, preventives and functional diets for diabetic diseases, esp., diabetes, contain phytic acid or its salt or salts. The salt of phytic acid is a non-toxious metal salt, or a non-toxious salt with an organic base, a basic amino acid or an organic ester residue, and has a compositional form together with or separately from phytic acid.

Abstract: A pharmaceutical composition containing as a pharmaceutically active ingredient at least one isomer of inositol triphosphate (IP.sub.3) in an amount sufficient to reduce the negative effect of cadmium or aluminium in the body or inhibit or reduce the formation of free radicals in the body.

Abstract: A food composition was prepared containing at least 5 mg of inositol triphosphate per 100 g of food. This composition was found to have utility in counteracting deliterious effects of heavy metals, radiation and smoking.

Abstract: An organic substrate, such as a pharmaceutical or biological system subject to degradation by oxidation and/or free radical formation, is stabilized by various inositol triphosphate compounds.

Abstract: A pharmaceutical composition containing as a pharmaceutically active ingredient at least one isomer of inositol triphosphate (IP.sub.3) in an amount sufficient to reduce the negative effect of cadmium or aluminum in the body or inhibit or reduce the formation of free radicals in the body.

Abstract: A method of making a food composition and the composition containing at least 5 mg of inositoltriphosphate.

Abstract: An antitumor agent of the present invention comprises, as an effective ingredient, lipoteichoic acid which is extracted from gram-positive bacterial cells.

Abstract: A method of improving the levels of formed blood elements in a patient having disease or therapy induced leukopenia comprising administering to said patient a therapeutically effective amount of a pharmaceutically acceptable, water or lipid soluble tertiary or quaternary amine having cholinergic or anticholinesterase activity.

Abstract: Compounds and compositions containing them, for insecticidal control have the formula ##STR1## in which R is an alkylene group having from 1 to 5 carbon atoms; R.sub.1 and R.sub.2 are methyl or ethyl; and R.sub.3 and R.sub.4 are independently n-propyl, branched chain alkyl groups having 3 or 4 carbon atoms, and branched alkyl groups having 5 carbon atoms and a branching at the .alpha.- or .beta.-carbon atom.